Projektbeschreibung
Ein neues Modell zur Arzneimittelentwicklung für Herz-Kreislauf-Erkrankungen
Herz-Kreislauf-Erkrankungen stellen die Ursache für 45 % aller Todesfälle in Europa dar und verursachen der EU-Wirtschaft jährlich Kosten in Höhe von 210 Millionen EUR. Angesichts dieser Zahlen sind unbedingt bessere und kosteneffizientere Behandlungsmethoden gefragt. Im Verlauf der vergangenen zehn Jahre wurden jedoch lediglich vier neue Arzneimittel gegen diese Erkrankungen zugelassen. Es sind Maßnahmen erforderlich, um die Arzneimittelentwicklung zu beschleunigen. Das EU-finanzierte Projekt EMAPS-Cardio zielt auf die Entwicklung einer neuen Organ-on-a-Chip-Plattform ab, die zur Züchtung und Reifung von kardialen Mikrogeweben für adultähnliche organotypische Modelle im gesunden und kranken Zustand dienen soll. Die höhere Sensibilität und Genauigkeit von Organ-on-a-Chip-Vorrichtungen ist zudem ein notwendiger technologischer Sprung, der die Entwicklung neuer Arzneimittel beschleunigen wird und Tiermodelle dabei überflüssig macht.
Ziel
Cardiovascular diseases (CVDs) account for 45% of deaths in Europe and are estimated to cost the EU economy €210 billion a year. However, only four drugs targeting cardiovascular diseases have been approved for use in the last decade. Thus, models that could effectively simulate diseased tissues, would enable the accurate assessment of the efficacy of the pharmaceuticals, and would accelerate drug development are urgently needed. The main bottleneck towards such models is the foetal-like state of the human induced pluripotent stem cell (hiPSC) derived cardiomyocytes (CMs). That is hiPSC-CMs do not reach adult-like maturity. The objective of this project is to produce a platform for growth and maturation of cardiac microtissues for adult-like organotypic models in healthy and diseased states. To achieve that, biomimetic microenvironment that provides all the needed stimuli (electrical, mechanical, topological (3D environment) and biochemical (release of active molecules)), during the maturation of hiPSC-CMs will be developed. This will be achieved by combining electro-mechanoactive polymer-based scaffolds (EMAPS) with bioactive membranes. To characterize the effects of CVD drugs, the contractility of the microtissue will be monitored continuously and simultaneously (over 24-wells) using the sensors developed during the project. To increase the sensitivity and accuracy of the model, deep-learning based algorithms to detect the effects of drugs in vitro will be developed and verified. The goals will be achieved by a multidisciplinary consortium with complementary know-how of three academic units and seven small companies. The increased sensitivity and accuracy of organ-on-chip devices is a needed leap in technology that will accelerate new drug development without the need for animal models; the project aims to provide a platform for the realization of such physiologically-relevant organotypic models.
Wissenschaftliches Gebiet
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
Schlüsselbegriffe
Programm/Programme
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-NMBP-TR-IND-2020-twostage
Finanzierungsplan
RIA - Research and Innovation actionKoordinator
75794 Paris
Frankreich